Amino acid substitutions in the melanoma antigen recognized by T cell 1 peptide modulate cytokine responses in melanoma-specific T cells

Journal of Immunotherapy

Volumn 23, Issue 4, 2000, Pages 405-411

  Nielsen, Mai Britt ^a   Kirkin, Alexei F ^b   Loftus, Douglas ^c   Nissen, Mogens Holst ^a   Rivoltini, Licia ^d   Zeuthen, Jesper ^b   Geisler, Carsten ^a   Odum, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cytotoxic T lymphocytes; Heteroclitic peptides; Immunotherapy; Interleukin 10; MART 1

Indexed keywords

MELANOMA ANTIGEN;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER IMMUNOLOGY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; RNA ANALYSIS;

AMINO ACID SUBSTITUTION; CYTOKINES; EPITOPES; HUMANS; IMMUNODOMINANT EPITOPES; INTERLEUKIN-10; INTERLEUKIN-13; NEOPLASM PROTEINS; PHOSPHORYLATION; PHOSPHOTYROSINE; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TH2 CELLS; TUMOR CELLS, CULTURED;

EID: 0033922703     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200007000-00003     Document Type: Article

References (23)

1. Rivoltini L, Loftus DJ, Squarcina P, et al. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T cell reactivity. Crit Rev Immunol 1998;18:55-64.
2. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18:267-8.
3. 27-35. Cancer Res 1998;58:2433-9.
4. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4: 321-7.
5. Valmori D, Fonteneau J-F, Lizana MC, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/ MART-1 immunodominant peptide analogues. J Immunol 1998; 160:1750-8.
6. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-37.
7. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell-receptor ligand on live antigen-presenting cells [Comment]. Nature 1993;363:117-18.
8. Evavold BD, Allen PM. Separation of IL-4 production from TH cell proliferation by an altered T cell receptor ligand. Science 1991; 252:1308-10.
9. Vergelli M, Hemmer B, Kalbus M, et al. Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells. J Immunol 1997;158: 3746-52.
10. Nicholson LB, Waldner H, Carrizosa AM, Sette A, Collins M, Kuchroo VK. Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity. Proc Natl Acad Sci USA 1998;95:264-9.
11. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10 treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells. Blood 1999;93:1634-42.
12. Rivoltini L, Squarcina P, Loftus DJ, et al. A superagonist variant of peptide MART1/MelanA27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implications for more effective immunotherapy. Cancer Res 1999;59:301-6.
13. Aruga A, Aruga E, Tanigawa K, Bisgop DK, Sondak VK, Chang AE. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 1997;159:664-73.
14. Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Derm 1997;108:914-19.
15. Hu H-M, Urba WJ, Fox BA. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 1998;161:3033-41.
16. Mosmann TR, Li L, Sad S. Functions of CD8 T-cell subset secreting different cytokine patterns. Semin Immunol 1997;9:87-92.
17. Kirkin AF, Petersen TR, Olsen AC, Li L, Thor Strafen P, Zeuthen J. Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol Immunother 1995;41:71-81.
18. Kirkin AF, Thor Straten P, Hansen MR, Barfoed A, Dzhandzhugazyan KN, Zeuthen J. Establishment of gp100 and MART-1/ Melan-A-specific CTL clones using in vitro immunization against highly immunogenic melanoma cell clones. Cancer Immunol Immunother 1999;48:239-46.
19. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-19.
20. Sato T, McCue P, Masuoka K, et al. Interleukin 10 production by human melanoma. Clin Cancer Res 1996;2:1383-90.
21. Dummer R, Yeu FY, Pavlovic J, et al. Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells:suppression by interleukin 10. Br J Cancer 1998;77:1413-19.
22. Yeu FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class -II and ICAM-1 molecules. Im J Cancer 1997;16: 630-7.
23. Romero P, Gervois N, Schneider J, et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997;159:2366-74.